Press Releases

Scientific Games Interactive Brings Fantasy to Reality with Sword of Destiny

SG Interactive’s Sword of Destiny™ introduces epic fantasy to the online gaming space. Bringing the magic aesthetic of the land-based original to online gaming, Sword of Destiny ushers players into a world of dynamic bonus rounds and remarkable visuals. Based on popular card games

October 24th, 2017|Press Center|

Deluxe Helps Answer Growing Demand for 4K Ultra HD Blu-ray™ Content with Dolby Vision Approved Authoring Services

Deluxe Entertainment Services Group (Deluxe) delighted cinephiles today with the announcement that its compression and authoring services are now Dolby Vision approved, which will rapidly facilitate the release of more high-quality 4K UHD Blu-ray content into the market. Deluxe has already delivered more than

October 17th, 2017|Press Center|

AM General Continues Growth Momentum with Additional $69M in Aftermarket Parts and Accessories Contracts

This comes on the heels of several key events for the company including the $2.2 Billon Foreign Military Sales requirements contract award, 2017 ISO/TS16949 Certification, and the ETI HMMWV / Hawkeye live fire exercise with International Delegations.

Global vehicles solutions provider, AM General, enhances its

October 11th, 2017|Press Center|

Deluxe Creates New Global Product & Technology Division: Deluxe Technologies

Deluxe today announced the formation of Deluxe Technologies. The new division will be comprised of over 250 engineers from six tech centers around the world with plans to significantly grow the size of the team over the next 12 months. Deluxe has played a key role

October 10th, 2017|Press Center|

AM General Awarded More Than $550 Million In New Global HMMWV Delivery Orders

Since award of an initial overarching Foreign Military Sales requirements contract less than a month ago, Company has already received multiple delivery orders for more than a quarter of the $2.2 billion, 5-year total contract potential value

Global demand for AM General’s current High Mobility

September 28th, 2017|Press Center|

Scientific Games to Acquire NYX Gaming Group

Scientific Games Corporation (Nasdaq: SGMS) (“Scientific Games”) and NYX Gaming Group Limited (TSXV: NYX) (“NYX”) today announced that they have entered into a definitive agreement (the “Arrangement Agreement”) under which Scientific Games will acquire NYX, further strengthening Scientific Games’ leadership position and ability to

September 20th, 2017|Press Center|

JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes

vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that JDRF, the leading global organization funding type 1 diabetes (T1D) research, will provide funding to support a Phase 2 Proof of Concept study to explore the effect of vTv Therapeutics’ liver-selective glucokinase (GK) activator TTP399 as

September 6th, 2017|Press Center|

Valassis to Acquire MaxPoint for $13.86 per Share in Cash

Valassis, a leader in intelligent media delivery, today announced that it has reached a definitive agreement, through its parent company Harland Clarke Holdings, to acquire MaxPoint Interactive (NASDAQ:MXPT), a leading digital marketing technology company. MaxPoint provides an industry-leading data management platform that fuels superior

August 27th, 2017|Press Center|

Global Demand for New HMMWVs Continues with AM General’s Newly Awarded 5-Year Foreign Military Sale Contract For Up to 11,560 HMMWVs

The U.S. Army Contracting Command today awarded global vehicle solutions provider AM General a 5-year, firm fixed price Foreign Military Sale (FMS) requirements contract to manufacture an estimated quantity of 11,560 new High Mobility Multipurpose Wheeled Vehicles (HMMWVs). The total value of the contract

August 27th, 2017|Press Center|

vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using Azeliragon

vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using azeliragon, the Company’s oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer’s disease.

August 3rd, 2017|Press Center|